Article metrics
PDF
Other content recommended for you
- Switching patients at high risk of PML from natalizumab to another disease-modifying therapy
- Update on disease-modifying therapies for multiple sclerosis
- Disease-modifying therapies for multiple sclerosis
- Pharmacovigilance during treatment of multiple sclerosis: early recognition of CNS complications
- Disease modifying therapies for relapsing multiple sclerosis
- Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data
- Dimethyl fumarate: a possible exit strategy from natalizumab treatment in patients with multiple sclerosis at risk for severe adverse events
- Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis
- Switching from natalizumab to alemtuzumab in patients with relapsing multiple sclerosis
- Effectiveness of autologous haematopoietic stem cell transplantation versus natalizumab in progressive multiple sclerosis